Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
COMPASS Pathways appoints Kabir Nath as Chief Executive Officer
Tuesday, July 19, 2022COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidencebased innovation in mental health today announced that it has appointed Kabir Nath as Chief Executive Officer effective August George Goldsmith CO...
Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent
Monday, July 18, 2022Fresenius Kabi announced today it will introduce a portfolio of generic contrast media agents in the United States starting immediately with the launch of Iodixanol Injection USP a product the US Food and Drug Administration FDA lists as being in sho...
Roche launches innovative dual antigen and antibody diagnostic test supporting the fight to eliminate the hepatitis C virus
Monday, July 18, 2022Roche announced the launch of the Elecsys HCV Duo immunoassay in countries that accept the CE Mark Elecsys HCV Duo is the first available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus HCV antigen and...
Nucleai Announces a Partnership with Sirona Dx for AI-Driven Discovery of Novel Spatial Biomarkers in Solid Tumors
Wednesday, July 13, 2022Nucleai a leader in AIpowered spatial biology transforming precision medicine by unlocking the power of pathology data and Sirona Dx a leading provider of multiomic singlecell analytical services today announced a collaboration to advance the discove...
FDA Accepts Byondis’ Biologics License Application for [Vic-]Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer
Tuesday, July 12, 2022Byondis BV an independent Dutch clinical stage biopharmaceutical company creating precision medicines announced today that the US Food Drug Administration FDA accepted the companys submission of a Biologics License Application BLA for victrastuzumab...
Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS
Tuesday, July 12, 2022Atara Biotherapeutics Inc a leader in Tcell immunotherapy leveraging its novel allogeneic EBV Tcell platform to develop transformative therapies for patients with cancer and autoimmune diseases today announced completion of the planned Interim Analys...
Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
Monday, July 11, 2022CanFite BioPharma Ltd a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory cancer and liver diseases announced today that it is planning to submit its registration plans to the US Food and Drug Ad...
INtRON Confirms Efficacy of CDL200 Against CDI Clinical Isolates
Monday, July 11, 2022INtRON Biotechnology announced today that CDL a novel biological drug candidate under the development of the worlds first enteric colontargeted capsule formulation for the treatment of intractable and recurrent CDI Clostridioides difficile Infection...
WuXi XDC and AbTis Sign Memorandum of Understanding for Development and Manufacturing of Antibody Drug Conjugates
Thursday, July 07, 2022WuXi XDC a global leading CRDMO dedicated to endtoend bioconjugates services and AbTis a Korean biotechnology company dedicated to the development of antibody drug conjugates ADC today announced that a Memorandum of Understanding MOU was signed to fo...
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Wednesday, July 06, 2022Alterity Therapeutics a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases today announced the first patient has been dosed in the Companys Phase clinical trial of ATH in Multiple System Atrophy...
